Partner Investment Management Lowers stake in Aerie Pharmaceuticals Inc (AERI)

Aerie Pharmaceuticals Inc (AERI) : Partner Investment Management reduced its stake in Aerie Pharmaceuticals Inc by 4.3% during the most recent quarter end. The investment management company now holds a total of 42,438 shares of Aerie Pharmaceuticals Inc which is valued at $1,686,911 after selling 1,907 shares in Aerie Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Aerie Pharmaceuticals Inc makes up approximately 2.89% of Partner Investment Management’s portfolio.

Other Hedge Funds, Including , Senzar Asset Management added AERI to its portfolio by purchasing 92,200 company shares during the most recent quarter which is valued at $3,664,950. Aerie Pharmaceuticals Inc makes up approx 0.95% of Senzar Asset Management’s portfolio.Harvey Capital Management Inc reduced its stake in AERI by selling 35,075 shares or 32.16% in the most recent quarter. The Hedge Fund company now holds 73,975 shares of AERI which is valued at $2,818,448. Aerie Pharmaceuticals Inc makes up approx 1.46% of Harvey Capital Management Inc’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in AERI in the latest quarter, The investment management firm added 56,319 additional shares and now holds a total of 685,163 shares of Aerie Pharmaceuticals Inc which is valued at $23,329,800.Alps Advisors Inc reduced its stake in AERI by selling 1,710 shares or 4.59% in the most recent quarter. The Hedge Fund company now holds 35,558 shares of AERI which is valued at $1,194,749. Aerie Pharmaceuticals Inc makes up approx 0.01% of Alps Advisors Inc’s portfolio.

Aerie Pharmaceuticals Inc closed down -1.5 points or -3.55% at $40.7 with 4,55,266 shares getting traded on Monday. Post opening the session at $42.5, the shares hit an intraday low of $40.6 and an intraday high of $43.4 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Many Wall Street Analysts have commented on Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals Inc was Initiated by Aegis Capital to “Buy” on Nov 1, 2016. Company shares were Reiterated by RBC Capital Mkts on Oct 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 49 from a previous price target of $48 .H.C. Wainwright Initiated Aerie Pharmaceuticals Inc on Sep 20, 2016 to “Buy”, Price Target of the shares are set at $66.

Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.

Leave a Reply

Aerie Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aerie Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.